WXXWY News and Press, Wuxi Biologics Cayman Inc ADR From 09/17/25

Three WuXi Biologics Manufacturing Facilities Receive GMP Certification from Türkiye İlaç ve Tibbi Cihaz Kurumu (TITCK) PR Newswire WUXI, China , Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, De...

WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards PR Newswire SINGAPORE , Sept. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced th...

WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry PR Newswire End-to-end Green CRDMO solutions to enable global clients for broader positive impact Span from biologics research, development, manufacturing, and overall operation...

WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi PR Newswire Committed to net-zero across the value chain by 2050 Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation Leader in Green CRDMO to drive innovation for a health...

WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale PR Newswire Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the techn...

WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules PR Newswire WuXia293 Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or si...

WuXi Biologics Named to A List for CDP Supplier Engagement Assessment PR Newswire Earns CDP's highest rating for supply chain engagement on climate Adds to other CDP recognition—Water Security A List and leadership score on climate change Drives sustainability t...

2025-08-06 09:24:00 ET Dear Baron Emerging Markets Fund Shareholder: Baron Emerging Markets Fund ® (the Fund) gained 15.39% (Institutional Shares) during the second quarter of 2025, while its primary benchmark, the MSCI Emerging Markets Index (the Benchmark), appreciated 11...

WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics PR Newswire Best ESG rating tier of negligible-risk with a top 1% global ranking score Industry and Regional ESG Top-Rated Company for five consecutive years Leader in Green CRDMO...

WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL PR Newswire The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrat...